Back to News
Market Impact: 0.25
Hiteck Licenses Investigational Next-Generation NGF Eye Drop HT006.2.2 to Visara for Neurotrophic Keratitis Outside Greater China
Source: PR Newswire
Healthcare & BiotechCompany Fundamentals
Hiteck granted its majority-owned ophthalmology subsidiary, Visara, exclusive worldwide rights outside Greater China to develop and commercialize HT006.2.2. Hiteck retains all rights in Greater China, where a Phase 1b study in severe neurotrophic [condition details are truncated] is underway; the article provides no financial terms.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
NBP0.50
More News
- South Korean carmaker Hyundai plans 'strategic' investment of $15.5 billion in India by 2032
- Applied Materials’ $5 billion AI lab aims to cut chip development time in half—and restore Silicon Valley’s edge
- Wells Fargo CFO on Earnings, Deals, Consumer Strength
- Bank of America hit with more than $1.2 billion in penalties over money-laundering violations
- Meta’s Muse models reach the AI frontier—and kill any hopes to ‘pace’ it
- We're upgrading our Goldman Sachs rating after a strong quarter bodes well for the future